Testing two treatment paths for active rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active, disabling rheumatoid arthritis despite trying a TNF-blocking biologic, or you had to stop it due to side effects or toxicity
- Your arthritis must be considered “active” on standard clinic scores (CDAI 10+ and HAQ 0.5+)
- If you take prednisone or NSAIDs, your dose must be stable for at least 2 weeks (prednisone equivalent must be 10 mg/day or less)
- You can keep a conventional arthritis medicine (methotrexate, sulfasalazine, hydroxychloroquine, or leflunomide) only if it’s been at a stable dose for at least 4 weeks—and for at least 3 months total
- You must be able to get medicines from both strategy groups through insurance or patient assistance
- You have not used more than 3 biologic medicines before, and you have not used targeted pill medicines before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
This study compares two combination treatments for rheumatoid arthritis in people whose current methotrexate or leflunomide isn’t working well enough. It aims to see whether adding a targeted therapy works better than the standard add-on of sulfasalazine plus hydroxychloroquine.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This study tests different targeted treatments for adults with rheumatoid arthritis who have already tried other biologic or targeted medications and need a new option. It aims to find which treatment works best for people like you.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.